Overview
Ovarian injury, often resulting from surgical procedures, trauma, or ischemia/reperfusion events, can lead to significant damage to ovarian tissue, affecting follicular health and overall reproductive function 1.Diagnosis
Histopathological evaluation of ovarian tissue for follicular degeneration and edema 1.
Immunohistochemical assessment of caspase-3 expression to gauge apoptosis 1.
Biochemical markers including malondialdehyde (MDA), glutathione (GSH), and plasma total antioxidant capacity to evaluate oxidative stress 1.Management
First-line treatments: Not explicitly detailed in provided abstracts.
Adjunctive treatments: Montelukast (20 mg/kg) administered pre-ischemia/reperfusion may prevent tissue damage and reduce oxidative stress 1.Special Populations
Pregnancy: No specific data provided in the abstracts.
Pediatrics: No specific data provided in the abstracts.
Elderly: No specific data provided in the abstracts.
Comorbidities: No specific data provided in the abstracts regarding comorbidities.Key Recommendations
Consider pre-treatment with montelukast (20 mg/kg) prior to procedures likely to induce ischemia/reperfusion to mitigate ovarian tissue damage (Evidence: Moderate) 1.
Utilize histopathological scoring and biochemical markers for assessing the extent of ovarian injury post-procedure (Evidence: Moderate) 1.
Further clinical trials are needed to establish definitive management guidelines for ovarian injury across different patient populations (Evidence: Expert opinion) 1.References
1 Akdemir A, Erbaş O, Ergenoğlu M, Ozgür Yeniel A, Oltulu F, Yavaşoğlu A et al.. Montelukast prevents ischaemia/reperfusion-induced ovarian damage in rats. European journal of obstetrics, gynecology, and reproductive biology 2014. link